Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Vigilância Sanitária em Debate |
Texto Completo: | https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008 |
Resumo: | Introduction: The use of medicinal plants as active plant pharmaceutical ingredients (APPIs) as well as the use of herbal medicines and their associations with other herbal medicines and synthetic active pharmaceutical ingredients (API) can result in interactions that affect the efficacy and safe use of these. The main means of reporting adverse drug reactions (ADR) is voluntary, which makes the identification and monitoring of these ADRs difficult and portrays the importance of pharmacovigilance in our country, highlighting the need to strengthen the culture of reporting adverse drug events (ADE). Objective: To analyze the occurrence of ADR related to the simultaneous use of five herbal medicines with other synthetics, describing possible synthetic APPI-API interactions. Method: A literature search was carried out on synthetic APPI-API interactions and their notifications of ADR by the main pharmacovigilance systems in the world. Results: The main interaction mechanisms between synthetic APPI-API involve the metabolism by enzymes of the CYP450 family or the action of efflux transporters such as P-gp. In addition, a large part of phytotherapeutic AEM may not be being notified, generating possible underreporting of this information in the world. Conclusions: On ADR containing APPI from Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum and Zingiber officinale, 7,571 were reported worldwide, classified by continent, in the period 1971 to August 2021, as well as the list of plant species on the list of RENISUS that have reported effects on CYP enzymes (1A2, 2C9, 2C19, 2D6 and 3A4), levels of GSH, UGT and P-gp activity. |
id |
FIOCRUZ-9_85fa80ac3b9f927193d56722d76e042d |
---|---|
oai_identifier_str |
oai:ojs.visaemdebate.incqs.fiocruz.br:article/2008 |
network_acronym_str |
FIOCRUZ-9 |
network_name_str |
Vigilância Sanitária em Debate |
repository_id_str |
|
spelling |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the marketFitovigilância: avaliação das interações e reações adversas de fitoterápicos no mercadoVigilância SanitáriaFitovigilânciaReações AdversasFitoterápicosEixo: Vigilância sanitária e sociedadeHealth SurveillancePhytosurveillanceAdverse ReactionsHerbal MedicinesIntroduction: The use of medicinal plants as active plant pharmaceutical ingredients (APPIs) as well as the use of herbal medicines and their associations with other herbal medicines and synthetic active pharmaceutical ingredients (API) can result in interactions that affect the efficacy and safe use of these. The main means of reporting adverse drug reactions (ADR) is voluntary, which makes the identification and monitoring of these ADRs difficult and portrays the importance of pharmacovigilance in our country, highlighting the need to strengthen the culture of reporting adverse drug events (ADE). Objective: To analyze the occurrence of ADR related to the simultaneous use of five herbal medicines with other synthetics, describing possible synthetic APPI-API interactions. Method: A literature search was carried out on synthetic APPI-API interactions and their notifications of ADR by the main pharmacovigilance systems in the world. Results: The main interaction mechanisms between synthetic APPI-API involve the metabolism by enzymes of the CYP450 family or the action of efflux transporters such as P-gp. In addition, a large part of phytotherapeutic AEM may not be being notified, generating possible underreporting of this information in the world. Conclusions: On ADR containing APPI from Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum and Zingiber officinale, 7,571 were reported worldwide, classified by continent, in the period 1971 to August 2021, as well as the list of plant species on the list of RENISUS that have reported effects on CYP enzymes (1A2, 2C9, 2C19, 2D6 and 3A4), levels of GSH, UGT and P-gp activity.Introdução: O uso de plantas medicinais como insumos farmacêuticos ativos vegetais (IFAV), bem como o uso de fitoterápicos e suas associações com outros medicamentos fitoterápicos e os insumos farmacêuticos ativos (IFA) sintéticos, pode resultar em interações que afetem a eficácia e o uso seguro desses. O principal meio de notificações de reação adversa a medicamento (RAM) é a voluntária, o que dificulta a identificação e o monitoramento dessas RAM e retrata a importância da farmacovigilância em nosso país, realçando a necessidade de fortalecimento da cultura de notificação de eventos adversos a medicamentos (EAM). Objetivo: Analisar a ocorrência de RAM relacionada ao uso simultâneo de cinco fitoterápicos a outros sintéticos, descrevendo as possíveis interações IFAV-IFA sintéticos. Método: Foi realizada pesquisa bibliográfica sobre as interações IFAV-IFA sintéticos e suas notificações de RAM pelos principais sistemas de farmacovigilância do mundo. Resultados: Os principais mecanismos de interação entre IFAV-IFA sintéticos envolvem a metabolização pelas enzimas da família CYP450 ou a ação de transportadores de efluxo como a gp-P. Além disso, grande parte dos EAM fitoterápicos podem não estar sendo notificados, gerando possível subnotificação dessas informações no mundo. Conclusões: Sobre RAM contendo IFAV de Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum e Zingiber officinale, foram relatados 7.571 no mundo, classificados por continente, no período de 1971 a agosto de 2021, bem como lista de espécies vegetais da lista do Renisus que apresentam efeitos relatados nas enzimas CYP (1A2, 2C9, 2C19, 2D6 e 3A4), níveis de GSH, UGT e atividade da gp-P. Instituto Nacional de Controle de Qualidade em Saúde2022-08-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed article""Artículo revisado por pares""Artigo avaliado pelos pares"application/pdfapplication/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/200810.22239/2317-269x.02008Health Surveillance under Debate: Society, Science & Technology ; Vol. 10 No. 3 (2022): August; 46-57Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 10 Núm. 3 (2022): Agosto; 46-57Vigil Sanit Debate, Rio de Janeiro; v. 10 n. 3 (2022): Agosto; 46-572317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1440https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1482Copyright (c) 2022 Ana Paula da Silva Roxo, Elizabeth Valverde Macedo , Samanta Cardozo Mourão , Thalita Gonçalves Barros, Emeli Moura de Araújo, Carlos Augusto de Freitas Peregrino, Marcela Miranda Salleshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccess Roxo, Ana Paula da SilvaValverde Macedo , ElizabethMourão , Samanta Cardozo Barros, Thalita GonçalvesMoura de Araújo, EmeliPeregrino, Carlos Augusto de Freitas Salles, Marcela Miranda2023-06-27T15:15:33Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/2008Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T15:15:33Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.none.fl_str_mv |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market Fitovigilância: avaliação das interações e reações adversas de fitoterápicos no mercado |
title |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market |
spellingShingle |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market Roxo, Ana Paula da Silva Vigilância Sanitária Fitovigilância Reações Adversas Fitoterápicos Eixo: Vigilância sanitária e sociedade Health Surveillance Phytosurveillance Adverse Reactions Herbal Medicines |
title_short |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market |
title_full |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market |
title_fullStr |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market |
title_full_unstemmed |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market |
title_sort |
Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market |
author |
Roxo, Ana Paula da Silva |
author_facet |
Roxo, Ana Paula da Silva Valverde Macedo , Elizabeth Mourão , Samanta Cardozo Barros, Thalita Gonçalves Moura de Araújo, Emeli Peregrino, Carlos Augusto de Freitas Salles, Marcela Miranda |
author_role |
author |
author2 |
Valverde Macedo , Elizabeth Mourão , Samanta Cardozo Barros, Thalita Gonçalves Moura de Araújo, Emeli Peregrino, Carlos Augusto de Freitas Salles, Marcela Miranda |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Roxo, Ana Paula da Silva Valverde Macedo , Elizabeth Mourão , Samanta Cardozo Barros, Thalita Gonçalves Moura de Araújo, Emeli Peregrino, Carlos Augusto de Freitas Salles, Marcela Miranda |
dc.subject.por.fl_str_mv |
Vigilância Sanitária Fitovigilância Reações Adversas Fitoterápicos Eixo: Vigilância sanitária e sociedade Health Surveillance Phytosurveillance Adverse Reactions Herbal Medicines |
topic |
Vigilância Sanitária Fitovigilância Reações Adversas Fitoterápicos Eixo: Vigilância sanitária e sociedade Health Surveillance Phytosurveillance Adverse Reactions Herbal Medicines |
description |
Introduction: The use of medicinal plants as active plant pharmaceutical ingredients (APPIs) as well as the use of herbal medicines and their associations with other herbal medicines and synthetic active pharmaceutical ingredients (API) can result in interactions that affect the efficacy and safe use of these. The main means of reporting adverse drug reactions (ADR) is voluntary, which makes the identification and monitoring of these ADRs difficult and portrays the importance of pharmacovigilance in our country, highlighting the need to strengthen the culture of reporting adverse drug events (ADE). Objective: To analyze the occurrence of ADR related to the simultaneous use of five herbal medicines with other synthetics, describing possible synthetic APPI-API interactions. Method: A literature search was carried out on synthetic APPI-API interactions and their notifications of ADR by the main pharmacovigilance systems in the world. Results: The main interaction mechanisms between synthetic APPI-API involve the metabolism by enzymes of the CYP450 family or the action of efflux transporters such as P-gp. In addition, a large part of phytotherapeutic AEM may not be being notified, generating possible underreporting of this information in the world. Conclusions: On ADR containing APPI from Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum and Zingiber officinale, 7,571 were reported worldwide, classified by continent, in the period 1971 to August 2021, as well as the list of plant species on the list of RENISUS that have reported effects on CYP enzymes (1A2, 2C9, 2C19, 2D6 and 3A4), levels of GSH, UGT and P-gp activity. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-08-31 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion "Peer-reviewed article" "Artículo revisado por pares" "Artigo avaliado pelos pares" |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008 10.22239/2317-269x.02008 |
url |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008 |
identifier_str_mv |
10.22239/2317-269x.02008 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1440 https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1482 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
dc.source.none.fl_str_mv |
Health Surveillance under Debate: Society, Science & Technology ; Vol. 10 No. 3 (2022): August; 46-57 Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 10 Núm. 3 (2022): Agosto; 46-57 Vigil Sanit Debate, Rio de Janeiro; v. 10 n. 3 (2022): Agosto; 46-57 2317-269X reponame:Vigilância Sanitária em Debate instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Vigilância Sanitária em Debate |
collection |
Vigilância Sanitária em Debate |
repository.name.fl_str_mv |
Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br |
_version_ |
1797042046636130304 |